Literature DB >> 16981823

Targeting the CB2 receptor for immune modulation.

Charles A Lunn1, Eva-Pia Reich, Loretta Bober.   

Abstract

Early work on the biology of the components of Cannabis sativa showed evidence for a potential influence on immune regulation. With the discovery of a peripheral cannabinoid receptor associated with immune cells, many laboratories have sought to link the immunoregulatory activities of cannabinoid compounds with this receptor, hoping that such compounds would lack the psychoactive effects of marijuana and other nonspecific cannabinoid agonists. In this report, the authors investigate the role of the cannabinoid CB2 receptor in immune regulation, with particular emphasis on compounds shown to regulate immune cell recruitment. The authors conclude by using the immune cell recruitment model to rationalise cannabinoid CB2 receptor-specific effects in modulating immune disease, particularly the increasing evidence for its role in experimental autoimmune encephalomyelitis and in influencing bone density.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16981823     DOI: 10.1517/14728222.10.5.653

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  16 in total

Review 1.  Current application of cannabidiol (CBD) in the management and treatment of neurological disorders.

Authors:  Brian Fiani; Kasra John Sarhadi; Marisol Soula; Atif Zafar; Syed A Quadri
Journal:  Neurol Sci       Date:  2020-06-16       Impact factor: 3.307

Review 2.  Enzymatic pathways that regulate endocannabinoid signaling in the nervous system.

Authors:  Kay Ahn; Michele K McKinney; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2008-04-23       Impact factor: 60.622

3.  CB₂ receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.

Authors:  Jeremy Koppel; Valerie Vingtdeux; Philippe Marambaud; Cristina d'Abramo; Heidy Jimenez; Mark Stauber; Rachel Friedman; Peter Davies
Journal:  Mol Med       Date:  2013-11-08       Impact factor: 6.354

4.  Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS.

Authors:  Santhi Gorantla; Edward Makarov; Deepa Roy; Jennifer Finke-Dwyer; L Charles Murrin; Howard E Gendelman; Larisa Poluektova
Journal:  J Neuroimmune Pharmacol       Date:  2010-06-12       Impact factor: 4.147

Review 5.  Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence.

Authors:  Uri Bright; Irit Akirav
Journal:  Int J Mol Sci       Date:  2022-05-15       Impact factor: 6.208

6.  CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.

Authors:  Jeremy Koppel; Valerie Vingtdeux; Philippe Marambaud; Cristina d'Abramo; Heidy Jimenez; Mark Stauber; Rachel Friedman; Peter Davies
Journal:  Mol Med       Date:  2014-03-14       Impact factor: 6.354

Review 7.  Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists.

Authors:  C A Lunn; E-P Reich; J S Fine; B Lavey; J A Kozlowski; R W Hipkin; D J Lundell; L Bober
Journal:  Br J Pharmacol       Date:  2007-10-01       Impact factor: 8.739

Review 8.  Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation.

Authors:  K L Wright; M Duncan; K A Sharkey
Journal:  Br J Pharmacol       Date:  2007-10-01       Impact factor: 8.739

9.  Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes.

Authors:  Vyvyca J Walker; Alisha P Griffin; Dagan K Hammar; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2016-03-21       Impact factor: 4.030

10.  Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids.

Authors:  Dmitry Grapov; Sean H Adams; Theresa L Pedersen; W Timothy Garvey; John W Newman
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.